Cargando…
Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children
Fibrinogen is a key coagulation protein, playing a critical role in hemostasis. It is the first factor to decrease to critical levels during bleeding. Hypofibrinogenemia is an important risk factor for bleeding in clinical settings, including pediatric surgery. Yet, the optimal measurement of fibrin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097151/ https://www.ncbi.nlm.nih.gov/pubmed/33968842 http://dx.doi.org/10.3389/fped.2021.617500 |
_version_ | 1783688297082519552 |
---|---|
author | Huisman, Elise J. Crighton, Gemma Louise |
author_facet | Huisman, Elise J. Crighton, Gemma Louise |
author_sort | Huisman, Elise J. |
collection | PubMed |
description | Fibrinogen is a key coagulation protein, playing a critical role in hemostasis. It is the first factor to decrease to critical levels during bleeding. Hypofibrinogenemia is an important risk factor for bleeding in clinical settings, including pediatric surgery. Yet, the optimal measurement of fibrinogen levels is subject to debate, as is the critical threshold for intervention. Fibrinogen replacement may be provided by cryoprecipitate and fibrinogen concentrate. Whilst both products contain fibrinogen, they are not equivalent, each has its own advantages and disadvantages, especially for pediatric use. Unfortunately, medical literature to support fibrinogen replacement in children is limited. In this article we review the current diagnostic tools to measure fibrinogen, with respect to their use in the pediatric critical care setting. Secondly, we evaluate the different fibrinogen replacement therapies, focusing on cryoprecipitate and fibrinogen concentrate and examine their individual product characteristics, associated risks and benefits, different dosing strategies and specific pitfalls for use in children. We summarize by highlighting current knowledge gaps and areas for future research. |
format | Online Article Text |
id | pubmed-8097151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80971512021-05-06 Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children Huisman, Elise J. Crighton, Gemma Louise Front Pediatr Pediatrics Fibrinogen is a key coagulation protein, playing a critical role in hemostasis. It is the first factor to decrease to critical levels during bleeding. Hypofibrinogenemia is an important risk factor for bleeding in clinical settings, including pediatric surgery. Yet, the optimal measurement of fibrinogen levels is subject to debate, as is the critical threshold for intervention. Fibrinogen replacement may be provided by cryoprecipitate and fibrinogen concentrate. Whilst both products contain fibrinogen, they are not equivalent, each has its own advantages and disadvantages, especially for pediatric use. Unfortunately, medical literature to support fibrinogen replacement in children is limited. In this article we review the current diagnostic tools to measure fibrinogen, with respect to their use in the pediatric critical care setting. Secondly, we evaluate the different fibrinogen replacement therapies, focusing on cryoprecipitate and fibrinogen concentrate and examine their individual product characteristics, associated risks and benefits, different dosing strategies and specific pitfalls for use in children. We summarize by highlighting current knowledge gaps and areas for future research. Frontiers Media S.A. 2021-04-21 /pmc/articles/PMC8097151/ /pubmed/33968842 http://dx.doi.org/10.3389/fped.2021.617500 Text en Copyright © 2021 Huisman and Crighton. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Huisman, Elise J. Crighton, Gemma Louise Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title | Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title_full | Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title_fullStr | Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title_full_unstemmed | Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title_short | Pediatric Fibrinogen PART I—Pitfalls in Fibrinogen Evaluation and Use of Fibrinogen Replacement Products in Children |
title_sort | pediatric fibrinogen part i—pitfalls in fibrinogen evaluation and use of fibrinogen replacement products in children |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097151/ https://www.ncbi.nlm.nih.gov/pubmed/33968842 http://dx.doi.org/10.3389/fped.2021.617500 |
work_keys_str_mv | AT huismanelisej pediatricfibrinogenpartipitfallsinfibrinogenevaluationanduseoffibrinogenreplacementproductsinchildren AT crightongemmalouise pediatricfibrinogenpartipitfallsinfibrinogenevaluationanduseoffibrinogenreplacementproductsinchildren |